

28 Projects

over which proof of concept has been established in either pre-clinical, phase 1 or phase 2 clinical studies.

Established drug formulations with data packages necessary for regulatory applications.

Proof of concept data from pre-clinical and clinical studies supporting the proposed therapeutic applications.

Regulatory filings for multiple drug products.

Granted and pending patents for manufacturing methods, drug formulations and methods of use to treat a range of conditions.

– Covers the entire drug development process from raw materials to patient dosing.

Clinical Project	Addressable Market Opportunity (in US\$)	Stage of Development	Regulatory Stage of Development	Next Steps	Relevant Patents
1. Lead Candidates					
IHL-42X Obstructive Sleep Apnea	\$8.24B (U.S.) by 2024 (s)	Phase 2/3 underway	Phase 2/3 trial completed	IND opening study	10x Pending Key claims deemed novel and inventive
IHL-675A Rheumatoid Arthritis	\$60.1B (U.S.) in 2021 (t)	Phase 2 completed	FDA Pre-IND completed	Complete phase 2 CT	16x Pending Key claims deemed novel and inventive
Psi-GAD Generalized Anxiety Disorder	\$4.26B (U.S.) by 2033, 9% CAGR (u)	Phase 2A	FDA IND submission	Complete phase 2B	Provisional patents filed
2. Secondary Assets					
IHL-675A Inflammatory Bowel Disease	\$21B (U.S.) in 2021 (v)	Pre-clinical completed	FDA Pre-IND completed	Commence phase 2 CT	16x Pending Key claims deemed novel and inventive
APIRx-1601 Skin: Vitiligo	\$0.1B (Global) in 2021 (b)	Phase 2 completed	Pre-IND drafting	Phase 1	1x Granted 1x Pending
APIRx-1602 Skin: Psoriasis	\$0.5B (Global) in 2021 (b)	Phase 2A completed	Pre-IND drafting	Phase 1	2x Pending
APIRx-1603 Skin: Atopic Dermatitis	\$1.1B (Global) in 2021 (b)	Phase 2A completed	Pre-IND drafting	Phase 1	1x Granted 1x Pending
CannQuit Addiction: Tobacco Smoking Cessation	\$47.75B (Global) by 2024, 17.3% CAGR (o)	Pre-clinical	Pre-regulatory	Phase 1	3x Granted
CannQuit O Addiction: Opioid Addiction	\$64B (U.S.) in 2021 (c)	Pre-clinical	Pre-regulatory	Phase 1	2x Granted

(d) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is Irritable Bowel Syndrome / Disease
 (b) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is medications and other, where other includes visits to physicians, in/out patient costs
 (c) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is Adolescent Substance Abuse
 (o) Worldwide Market Reports, "Smoking Cessation and Nicotine De-Addiction Products Market", May 2018
 (s) <https://www.mordorintelligence.com/industry-reports/global-sleep-apnea-devices-market-industry>

(t) <https://www.globenewswire.com/en/news-release/2023/02/10/2605710/0/en/Trending-Global-Rheumatoid-Arthritis-Drugs-Market-Size-Share-to-Hit-70-1-Billion-by-2030-at-a-1-75-CAGR-Growing-cases-of-rheumatoid-arthritis-to-propel-market-demand-Facts-Factors.html>
 (u) <https://www.futuremarketinsights.com/reports/generalized-anxiety-disorder-treatment-market>
 (v) <https://www.alliedmarketresearch.com/inflammatory-bowel-disease-drugs-market-Size-Growing-at-5-2-CAGR-Set-to-Reach-USD-60-3-Billion-By-2032.html>



Additional Pipeline Assets

Clinical Project	Addressable Market Opportunity (in US\$)	Stage of Development	Regulatory Stage of Development	Next Steps	Relevant Patents
IHL-675A Inflammatory Lung Disease	\$36.7B (U.S.) (COPD and Asthma) in 2022 (w)	Pre-clinical completed	FDA Pre-IND completed	Commence phase 2 CT	2x Pending Deemed novel & inventive
IHL-216A TBI/Concussion	\$3.46B (U.S.) in 2022 (x)	Pre-clinical completed	FDA Pre-IND scheduled (Sept. 2022)	IND opening study	1x Granted 6x Pending
MedChew™-1401 Pain and Spasticity in Multiple Sclerosis	\$62B (Global) in 2021 (a)	Pre-clinical	Pre-IND completed in NL and Switzerland	Phase 1	Granted
MedChew™ GB Post-herpetic Neuralgia	\$3.7B (U.S.) by 2027 (n)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™-1502 Parkinson's Disease	\$8.05B (Global) by 2027; 6.5% CAGR (l)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™-1503 Dementia	\$23.9B (Global) by 2028; 7.9% CAGR (m)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™ RL Restless Legs Syndrome	12.1% prevalence of U.S. pop. (j)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™ Dronabinol Nausea and Vomiting in Chemotherapy	\$3.1B (Global) by 2024 (e)	Phase 1A completed	FDA Pre-IND completed	Phase 1B	Granted
APIRx 1505 Flotex Gastro: Crohn's Disease	\$12.6B (Global) by 2024 (k)	Pre-clinical	Pre-regulatory	Phase 1	Drafting
CanChew Plus Gastro: IBS	\$40B (U.S.) in 2021 (d)	Phase 2A Completed	Pre-IND, ethics approval	Phase 2B	Granted
CanChew RX Gastro: IBD	\$2.78B (U.S.) by 2028 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
SuppoCan (Suppository) Gastro: IBD	\$2.78B (U.S.) by 28 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
Oraximax Gingivitis and Periodontitis	\$42B (U.S. and Europe) in 2021 (a)	Clinical Stage	510(k) pre-market submission to FDA	Phase 2	Granted
CheWell Addiction: Cannabis Dependence	\$64B (U.S.) in 2021 (c)	Pre-clinical	Pre-IND ready for submission	Phase 1	Drafting
APIRx-1701 Oph: Glaucoma	\$10.4B (Global) by 2026, 6.3% CAGR (g)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
APIRx-1702 Oph: Dry Eye Syndrome	\$6.6B (Global) by 2027, 6.4% CAGR (p)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
APIRx-1801 Ultrapure THC	\$31.5B (Global) by 2030, 18.6% CAGR (q)	Developed			Granted
APIRx-1802 Ultrapure CBD	\$31.5B (Global) by 2030, 18.6% CAGR (q)	Developed			Granted
APIRx-1803 Ultrapure CBG	\$31.5B (Global) by 2030, 18.6% CAGR (q)	Developed			Granted

(a) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021

(g) ResearchandMarkets, "Outlook on the Glaucoma Therapeutics Global Market", 2020-2026", Oct. 22, 2021

(l) Global Market Insights, "Parkinson's Disease Therapeutics Market", Base Year 2020

(j) Straits Research: Home Care Sleep Screening Devices Market

(k) Heraldkeepers, "Crohn's Disease Drugs Market Research Report 2022: Prospects, Trends Analysis, Market Size and Forecasts to 2027", Jan. 2, 2022

(m) Accurize Market Research, "Dementia Drugs Treatment Market", Nov. 27, 2021

(n) Comserve, "U.S. Shingles Vaccine Market", Jan. 4, 2022

(e) Healdkeepers, "Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Research Report, History and Forecast 2022-2027", Jan. 2, 2022

(p) Future Market Insights, "Dry Eye Syndrome Treatment Market", July 2017

(q) Precedence Research "Cannabis Extract Market", Mar. 2020; includes THC, CBD, CBG and other

(w) <https://www.globenewswire.com/news-release/2023/03/17/2629585/0/en/Asthma-and-COPD-Drug-Market-Size-Growing-at-5-2-CAGR-Set-to-Reach-USD-60-3-Billion-By-2032.html>

(x) <https://www.databridgemarketresearch.com/reports/global-traumatic-brain-injuries-treatment-market>